Trading Signals: IOVA Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Iovance Biotherapeutics Inc)
| IOVA latest price $23.7200 (-5.76%) ($21.7700 - $24.5400) on Fri. Aug. 2, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.89% (three month average) | RSI | 48 | Latest Price | $23.7200(-5.76%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | IOVA declines -1% a day on average for past five trading days. | Weekly Trend | IOVA declines -1% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support IOVA advance at 0% a week (0% probability) IBB(49%) XBI(49%) ARKG(47%) IWO(44%) ARKK(42%) | Factors Impacting IOVA price | IOVA will decline at least -2.945% in a week (0% probabilities). VIXM(-28%) VXX(-16%) UUP(-9%) IFRA(-6%) TLT(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.945% (StdDev 5.89%) | Hourly BBV | 0 () | Intraday Trend | 8% | | | |
|
Resistance Level | $24.78 | 5 Day Moving Average | $24.58(-3.5%) | 10 Day Moving Average | $24.94(-4.89%) | 20 Day Moving Average | $24.78(-4.28%) | To recent high | -8.8% | To recent low | 133.2% | Market Cap | $3.473b | | | | Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. |